Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CCCC 
C4 Therapeutics Inc (CCCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/30/2025: CCCC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.14
1 Year Target Price $11.14
| 4 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.47% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 196.74M USD | Price to earnings Ratio - | 1Y Target Price 11.14 |
Price to earnings Ratio - | 1Y Target Price 11.14 | ||
Volume (30-day avg) 8 | Beta 2.89 | 52 Weeks Range 1.08 - 4.26 | Updated Date 12/30/2025 |
52 Weeks Range 1.08 - 4.26 | Updated Date 12/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.67 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -210.86% |
Management Effectiveness
Return on Assets (TTM) -23.2% | Return on Equity (TTM) -59.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 75037566 | Price to Sales(TTM) 6.53 |
Enterprise Value 75037566 | Price to Sales(TTM) 6.53 | ||
Enterprise Value to Revenue 2.49 | Enterprise Value to EBITDA -0.42 | Shares Outstanding 96914418 | Shares Floating 60931064 |
Shares Outstanding 96914418 | Shares Floating 60931064 | ||
Percent Insiders 7.19 | Percent Institutions 72.54 |
Upturn AI SWOT
C4 Therapeutics Inc
Company Overview
History and Background
C4 Therapeutics, Inc. (C4T) was founded in 2017 as a spin-out from Dana-Farber Cancer Institute. The company leverages pioneering work in the field of proteolysis targeting chimeras (PROTACs) and other targeted protein degraders. Its mission is to create a new generation of medicines that degrade disease-driving proteins. Significant milestones include its initial funding rounds, the establishment of its proprietary drug discovery platform, and its progression into clinical trials for its lead drug candidates.
Core Business Areas
- Drug Discovery and Development: C4 Therapeutics focuses on the discovery and development of novel small molecule therapeutics that harness the body's natural protein degradation pathways to selectively remove disease-causing proteins. Their platform allows for the identification of novel degraders with potential applications across various therapeutic areas, primarily oncology and rare genetic diseases.
Leadership and Structure
C4 Therapeutics is led by a team of experienced scientists and drug developers, with a board of directors overseeing strategic direction. The organizational structure is typical for a biotechnology company, with strong emphasis on research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- CFT8634: CFT8634 is a selective degrader of IKZF1/3, being developed for the treatment of hematologic malignancies, including multiple myeloma. It is currently in Phase 1 clinical trials. Competitors in this space include companies developing other novel therapeutics for multiple myeloma and related blood cancers.
- CFT1946: CFT1946 is a selective degrader of the BTK protein, intended for the treatment of various B-cell malignancies. It is also in Phase 1 clinical trials. Competitors include companies developing BTK inhibitors and other targeted therapies for B-cell lymphomas and leukemias.
- CFT2222: CFT2222 is a selective degrader of the GSPT1 protein, intended for the treatment of certain solid tumors and hematologic malignancies. It is in preclinical development. Competitors are those developing novel oncology therapeutics targeting similar pathways or indications.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the oncology and rare diseases sectors, is characterized by rapid innovation, significant investment in research and development, and a growing demand for novel and effective treatments. The field of targeted protein degradation is an emerging and exciting area with the potential to revolutionize drug discovery.
Positioning
C4 Therapeutics is positioned as a pioneer in the targeted protein degradation space. Its competitive advantages lie in its proprietary platform, its deep scientific expertise in PROTAC technology, and its focus on developing degraders for previously 'undruggable' targets. The company aims to be a leader in this novel therapeutic modality.
Total Addressable Market (TAM)
The TAM for C4 Therapeutics' target indications, primarily oncology and rare genetic diseases, is substantial and growing. The oncology market alone is valued in the hundreds of billions of dollars globally, with specific indications like multiple myeloma and B-cell malignancies representing multi-billion dollar markets. C4 Therapeutics is positioned to capture a significant portion of this TAM by developing first-in-class degraders.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform for targeted protein degradation.
- Experienced scientific and leadership team with expertise in PROTAC technology.
- First-mover advantage in developing novel degraders for difficult-to-drug targets.
- Strong preclinical data for lead drug candidates.
- Potential for broad applicability across various diseases.
Weaknesses
- Early-stage company with limited commercialized products.
- High research and development costs associated with drug development.
- Dependence on clinical trial success for future revenue.
- Potential for complex manufacturing and regulatory hurdles for novel modalities.
Opportunities
- Expansion into new therapeutic areas beyond oncology.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Advancements in AI and machine learning for drug discovery and development.
- Growing understanding and acceptance of targeted protein degradation as a therapeutic strategy.
- Potential for combination therapies with existing treatment modalities.
Threats
- Competition from other companies developing targeted protein degraders.
- Failure of clinical trials leading to significant setbacks.
- Changes in regulatory landscape for novel drug modalities.
- Intellectual property challenges and patent disputes.
- Economic downturns impacting R&D funding and investment.
Competitors and Market Share
Key Competitors
- Arvinas Inc. (ARVN)
- Kymera Therapeutics Inc. (KYMR)
- Nurix Therapeutics, Inc. (NRIX)
Competitive Landscape
C4 Therapeutics' advantage lies in its specific focus and platform innovation within targeted protein degradation. However, it faces strong competition from other established players in the PROTAC and molecular glues space. Competitors like Arvinas have advanced clinical-stage assets, while Kymera and Nurix are also developing broad pipelines of protein degraders. Differentiation will be key, through novel target selection, drug design, and demonstrating superior efficacy and safety profiles.
Growth Trajectory and Initiatives
Historical Growth: C4 Therapeutics' historical growth has been centered on building its scientific platform, advancing its lead drug candidates into clinical development, and securing funding to support its R&D activities. The company has shown progress in advancing its pipeline from discovery to clinical stages.
Future Projections: Future growth projections are contingent on the successful outcome of its ongoing clinical trials for CFT8634 and CFT1946, and the progression of its preclinical assets. Positive clinical data leading to potential regulatory approvals would be the primary driver of significant revenue growth and market expansion. Analyst estimates would focus on potential peak sales of its lead candidates and the long-term impact of its platform technology.
Recent Initiatives: Recent initiatives include advancing its lead drug candidates into Phase 1 clinical trials, expanding its research into new therapeutic targets, and potentially engaging in strategic partnerships to accelerate development and commercialization.
Summary
C4 Therapeutics is a promising early-stage biotechnology company at the forefront of targeted protein degradation. Its innovative platform and focus on novel drug candidates for oncology and rare diseases offer significant potential. However, the company faces the inherent risks of drug development, including clinical trial failures and intense competition. Continued progress in clinical trials and successful strategic partnerships will be crucial for its long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Presentations
- Reputable Financial Data Providers (e.g., Bloomberg, Refinitiv, Yahoo Finance)
- Industry Research Reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The data presented is based on publicly available information and may not be exhaustive or perfectly accurate. Investment decisions should be made in consultation with a qualified financial advisor. Market share data is illustrative and based on general industry understanding of the competitive landscape in targeted protein degradation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About C4 Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-10-02 | CEO, President & Director Mr. Andrew J. Hirsch M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 110 | Website https://www.c4therapeutics.com |
Full time employees 110 | Website https://www.c4therapeutics.com | ||
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.